Covishield and Covaxin, the two COVID-19 vaccines, which have received Emergency Use Authorisation (EAU) in India
According to the recently published study, SARS-CoV-2 may resemble the mild cold-causing coronaviruses
Delhi Police formed a green corridor to safely transport the COVID-19 vaccine from airport to the hospital, the Delhi government's largest COVID-19 facility
Covishield is developed by Oxford University and British-Swedish company AstraZeneca and manufactured by the Serum Institute of India
The first phase of the COVID-19 vaccination drive in India will begin from January 16 with 30 crore people in the priority group
The share of active cases in the total positive cases has further compressed to 2.07 per cent of the cumulative caseload, stated the Ministry of Health...
India will receive 1.1 crore COVID-19 vaccine doses from the Serum Institute of India and 55 lakh from Bharat Biotech by January 14
Scientists typically estimate that a vaccination rate of about 70 per cent is needed for herd immunity, where entire populations are protected against a disease
The COVID-19 vaccine Sputnik V's efficacy is confirmed at 91.4 per cent based on data analysis of the final control point of clinical trials in Russia
The second dry run for COVID-19 vaccination was conducted in Uttar Pradesh's Gautam Buddh Nagar district on Monday (January 11)
PM Modi said that besides the two vaccines, Covishield developed by Oxford and British-Swedish company AstraZeneca and manufactured by Serum Institute of India, and Bharat Biotech's...
The COVID-19 vaccination drive in the country will start on January 16 with priority group involving healthcare and frontline workers